Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose, dose-escalation study of LY3303560 in Alzheimer's disease
jRCT2080223501Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing LY3303560 with Placebo (2 arms). Primary endpoints: Safety and tolerability of LY3303560, Pharmacokinetics of LY3303560 and 1 more. Started Apr 2017; status: recruiting.
02
Drugs
zagotenemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on jRCT2080223501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223501.